The new market research report from Technavio presents a complete segmentation of the global insomnia market by types of formation and disorder condition. It discusses the major drivers influencing the market growth and the challenges faced by vendors and the market as a whole. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the market, including Eisai, Merck, Pfizer, Sanofi, and Takeda.
Technavio’s market research analysts estimate the global insomnia market to decline at a CAGR of over 3% due to the dominance of generic products, patent erosion, poor patient compliance, and the diagnosis rate. The Americas account for 71% of global insomnia drugs market, closely followed by EMEA and APAC. This market study report predicts Americas’ share to decrease during the forecast period due to the patent expiry of Eisai’s Lunesta in the US. However, the vendors in US are entering strategic alliances for drug development and distribution.
“New drugs formulations are triggering end-users to accept more drug treatments for insomnia. Through the reformulation strategy, vendors are releasing extended versions of their approved products, which are safer and more effective than the existing ones. For instance, Sanofi launched a controlled-release formulation of Ambien, which decreases dosing frequency by ensuring extended drug action. Also, manufacturers emphasize on taking sublingual tablets over oral tablets in the treatment process because the former acts quickly and evades first-pass metabolism,” says Imran Mushtaq, Lead Analyst, Healthcare, Technavio Research.
Late-night working shifts, depression syndromes, travel across time zones, and ageing are the factors identified by the research study that can result in insomnia. The occurrence of insomnia is around 2 times higher in women than in men, due to hormonal changes associated with the premenstrual dysphoric disorder. As per an UN market analysis, the instances of insomnia in aging population is higher because of other problems, such as breathing disorders, which cause troubled sleep. Moreover, insomnia has a low diagnosis rate due to the lack of its awareness and identification of symptoms.
The key vendors in the global insomnia market are Eisai, Merck, Pfizer, Sanofi, and Takeda. Intense competition prevails among vendors due the presence of large vendors offering branded products and smaller vendors offering generic drugs. Manufacturers are focusing to offer drugs with a superior safety profile and long-term efficacy.
A more detailed analysis is available in the Technavio report, Global Insomnia Market – Market Research Analysis 2015-2019.
https://www.technavio.com/%3Cp%3E%3Cstrong%3EWe%20can%20customize%20repor…
